{
  "abstract": "Introduction: In the phase III RATIONALE-315 trial (NCT04379635), perioperative tislelizumab plus neoadjuvant chemotherapy significantly improved overall and event-free survival versus placebo plus chemotherapy in patients with resectable stage II–IIIA non–small cell lung cancer (NSCLC). Here, report prespecified patient-reported outcomes (PROs).\n\nMethods: PROs were evaluated using the EORTC QLQ-C30 and QLQ-LC13 questionnaires. A mixed-effects model for repeated measures was used for PRO endpoints at neoadjuvant Cycle 3 and adjuvant Cycles 3, 5, and 7. Time to deterioration (TTD) was also analyzed.\n\nResults: 453 patients were randomized to tislelizumab (n = 226) or placebo (n = 227). At adjuvant Cycles 3 and 5, chest pain was maintained with tislelizumab versus worsening with placebo (LSM difference −4.99 [95% CI: −9.06 to −0.93]; p = 0.016) and −4.15 [95% CI: −7.86 to −0.44]; p = 0.028, respectively). At adjuvant Cycle 7, greater improvement in coughing was observed in the tislelizumab arm versus placebo (−5.10 [95% CI: −9.79 to −0.40]; p = 0.034). TTD analysis showed a lower risk of chest pain with tislelizumab (HR 0.58; p = 0.004).\n\nConclusion: Perioperative tislelizumab improved coughing and chest pain compared with placebo in patients with resectable NSCLC. These data provide additional support of this regimen in this patient population.\n\nClinical trial registration: www.clinicaltrials.gov identifier is NCT04379635.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China",
    "Division of Medical Oncology, Istituto Nazionale Tumori IRCCS Regina Elena, Rome, Italy",
    "The Second Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, Hunan, China",
    "Department of Thoracic Surgery, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China",
    "Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China",
    "Department of Clinical Development, BeOne Medicines (Shanghai), Co., Ltd., Shanghai, China",
    "Department of Biostatistics/Clinical Development, BeOne Medicines (Beijing), Co., Ltd., Beijing, China",
    "Department of Patient-Reported Outcomes Function, Global Medical Affairs, BeOne Medicines USA, Inc., San Mateo, CA, USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Dongsheng Yue"
    },
    {
      "affs": [
        1
      ],
      "name": "Federico Cappuzzo"
    },
    {
      "affs": [
        2
      ],
      "name": "Wenxiang Wang"
    },
    {
      "affs": [
        3
      ],
      "name": "Hongxu Liu"
    },
    {
      "affs": [
        4
      ],
      "name": "Qixun Chen"
    },
    {
      "affs": [
        5
      ],
      "name": "Shengfei Wang"
    },
    {
      "affs": [
        5
      ],
      "name": "Shiang Jiin Leaw"
    },
    {
      "affs": [
        6
      ],
      "name": "Bin Yao"
    },
    {
      "affs": [
        7
      ],
      "name": "Frederick B. Barnes"
    },
    {
      "affs": [
        7
      ],
      "name": "Gisoo Barnes"
    },
    {
      "affs": [
        0
      ],
      "name": "Changli Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/eqf84xtmjcvdp.bib",
  "cited_by": 0,
  "doi": "10.1080/14796694.2026.2743385",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13757690/",
  "id": "eqf84xtmjcvdp",
  "issns": [
    "1479-6694",
    "1744-8301"
  ],
  "landing_url": "https://doi.org/10.1080/14796694.2026.2743385",
  "language": "en",
  "licence": "CC-BY-NC-ND-4.0",
  "licence_label": "CC BY-NC-ND 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2740|Lung Cancer Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7225383745",
  "pdf_url": "https://www.tandfonline.com/doi/pdf/10.1080/14796694.2026.2743385?needAccess=true",
  "pmcid": "PMC13757690",
  "pmid": "42990047",
  "published": "2026-11-06",
  "publisher": "Taylor & Francis",
  "ris": "https://research.draconitic.com/paper/eqf84xtmjcvdp.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:23:16Z",
      "native_id": "PMC13757690",
      "source": "pmc",
      "url": "https://doi.org/10.1080/14796694.2026.2743385"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Diagnosis and Treatment",
      "subfield": "general"
    }
  ],
  "title": "Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial",
  "title_text": "Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T12:23:16Z",
  "url": "https://research.draconitic.com/paper/eqf84xtmjcvdp",
  "venue": "Future Oncology",
  "versions": []
}